A Dual-Armed Oncolytic Virus Shows Clinical Efficacy in Advanced Solid Cancers.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 38935348.
- Also identified by DOI 10.1158/1078-0432.CCR-24-1126.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An oncolytic adenovirus armed with tumor necrosis factor-α and interleukin-2 was tested in patients with advanced solid tumors. Antitumor effects were observed in both treated and non-treated lesions, leading to long-term survival in some patients. This clinical trial shows the potential of oncolytic virotherapy for patients refractory to standard therapies. See related article by Pakola et al., p. 3715.
Medical subject headings
- Oncolytic Virotherapy
- Neoplasms
- Oncolytic Viruses
- Adenoviridae
- Interleukin-2